HLA-A*31:01 and HLA-B*15:02 as Genetic Markers for Carbamazepine Hypersensitivity in Children

Phenotype Standardization for Immune-Mediated Drug-Induced Skin Injury

(2011) M Pirmohamed et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population

(2011) Cecilie Johannessen Landmark et al.   EPILEPSY RESEARCH

Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans

(2011) Sae-Hoon Kim et al.   EPILEPSY RESEARCH

Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients

(2011) Yan Zhang et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

The current understanding of Stevens–Johnson syndrome and toxic epidermal necrolysis

(2011) Maja Mockenhaupt   Expert Review of Clinical Immunology

Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome

(2011) Tai-Ming Ko et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Carbamazepine-Induced Toxic Effects and HLA-B*1502 Screening in Taiwan

(2011) Pei Chen et al.   NEW ENGLAND JOURNAL OF MEDICINE

HLA-A*3101 and Carbamazepine-Induced Hypersensitivity Reactions in Europeans

(2011) Mark McCormack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Recurrence and Outcomes of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children

(2011) Y. Finkelstein et al.   PEDIATRICS

Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland

(2011) Qian Wang et al.   SEIZURE-EUROPEAN JOURNAL OF EPILEPSY

ALDEN, an Algorithm for Assessment of Drug Causality in Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Comparison With Case–Control Analysis

(2010) B Sassolas et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients

(2010) Nahoko Kaniwa et al.   EPILEPSIA

Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population

(2010) Wichittra Tassaneeyakul et al.   EPILEPSIA

Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China

(2010) X.T. Wu et al.   EPILEPSY & BEHAVIOR

Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population

(2010) Takeshi Ozeki et al.   HUMAN MOLECULAR GENETICS

Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations

(2010) F. F. Gonzalez-Galarza et al.   NUCLEIC ACIDS RESEARCH

Identifying genomic and developmental causes of adverse drug reactions in children

(2010) Mara L Becker et al.   PHARMACOGENOMICS

HLA Class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions

(2009) Hiroko Ikeda et al.   EPILEPSIA

Association of HLA-BFNx011502 allele and carbamazepine-inducedStevens-Johnson syndromeamong Indians

(2009) TimirY Mehta et al.   Indian Journal of Dermatology Venereology & Leprology

Medications as Risk Factors of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children: A Pooled Analysis

(2009) N. Levi et al.   PEDIATRICS

Adverse drug reaction active surveillance: developing a national network in Canada's children's hospitals

(2009) BC Carleton et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Application of principal component analysis to pharmacogenomic studies in Canada

(2009) H Visscher et al.   PHARMACOGENOMICS JOURNAL

Antiepileptic drug utilization in children from 1997–2005—a study from the Netherlands

(2008) N. W. van de Vrie-Hoekstra et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY